VTYX Ventyx Biosciences, Inc.: institutional ownership and insider trading
2 funds reported holding $36.0M of Ventyx Biosciences, Inc. in their latest 13F filings; in Q2 2026 funds net bought $0, with 0 new positions and 1 funds selling out; over the last 12 months insiders bought $0 and sold $463K on the open market.
VTYX revenue and earnings
- Quarter ended Sep 30, 2025: revenue n/a, net income −$22.8M, EPS -0.32
- Quarter ended Jun 30, 2025: revenue n/a, net income −$27.0M, EPS -0.38
- Quarter ended Mar 31, 2025: revenue n/a, net income −$27.4M, EPS -0.39
- Quarter ended Dec 31, 2024: revenue n/a, net income −$29.4M, EPS -0.35
Largest institutional holders of VTYX
- VANGUARD GROUP INC — $35.6M
- Nuveen Asset Management, LLC — $369K
Recent VTYX insider trades
- Dec 18, 2025: Mohan Raju sold 47,345 shares ($366K)
- Dec 18, 2025: Nuss John sold 12,675 shares ($97.9K)
- Apr 2, 2025: Nuss John sold 1,887 shares ($2.02K)
- Dec 27, 2024: Nuss John sold 21,119 shares ($49.8K)
5%+ owners
- Somasundaram Subramaniam: 7.6% (Schedule 13D/A, filed Mar 12, 2025)
- Raju Mohan: 6.0% (Schedule 13D/A, filed Jan 9, 2026)
- Affinity Healthcare Fund, LP: 5.7% (Schedule 13G, filed May 30, 2025)
- The Vanguard Group: 5.3% (Schedule 13G, filed Oct 31, 2025)